EQUASENS (formerly Pharmagest Interactive): RESULTS OF THE VOTE ON THE RESOLUTIONS PRESENTED TO THE ANNUAL ORDINARY GENERAL MEETING OF JUNE 28, 2022


Villers-lès-Nancy, July 6, 2022 – 7:00 p.m. (CET)

PRESS RELEASE

RESULTS OF THE VOTE ON THE RESOLUTIONS PRESENTED
TO THE ORDINARY ANNUAL GENERAL MEETING
FROM 28 JUNE 2022

Number of shares making up the share capital : 15.174.125

Number of shares entitled to vote : 15.005.340

Number of shares, with voting rights, owned by shareholders present or represented or having voted by mail : 13.143.135

The Annual Ordinary General Meeting met on Tuesday June 28, 2022 at 5 p.m. at the Company’s registered office and approved the parent company and consolidated financial statements for the 2021 financial year. Board of Directors is as follows:

Resolutions

Voting Results

  • FIRST RESOLUTION
    Approval of the annual accounts
Resolution adopted by:

  • 13,129,759 votes for
  • 0 votes against
  • 13,376 abstentions
  • SECOND RESOLUTION
    Discharge to the Directors and discharge of the performance of their mission to the Statutory Auditors
Resolution adopted by:

  • 13,020,494 votes for
  • 109,265 votes against
  • 13,376 abstentions
  • THIRD RESOLUTION
    Approval of consolidated accounts
Resolution adopted by:

  • 13,129,759 votes for
  • 0 votes against
  • 13,376 abstentions
  • FOURTH RESOLUTION
    Appropriation of earnings and setting of the dividend
Resolution adopted by:

  • 13,142,925 votes for
  • 210 votes against
  • 0 abstentions
  • FIFTH RESOLUTION
    Agreements and commitments referred to in Article L. 225-38 of the French Commercial Code
Resolution adopted by

  • :
  • 2,855,465 votes for
  • 146,856 votes against
42 abstentionsApproval of information relating to the compensation of corporate officers paid during the 2021 financial year, or awarded for the same financial year and mentioned in Article L. 22-10-9 of the French Commercial Code

  • Resolution adopted by:
  • 12,620,491 votes for
  • 522,392 votes against
252 abstentionsApproval of the elements of compensation paid during the 2021 financial year to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors

  • Resolution adopted by:
  • 13,131,917 votes for
  • 11,210 votes against
8 abstentionsApproval of the elements of compensation paid during the 2021 financial year to Mr. Dominique PAUTRAT, Chief Executive Officer

  • Resolution adopted by:
  • 11,304,037 votes for
  • 1,838,823 votes against
275 abstentionsApproval of the elements of compensation paid during the 2021 financial year to Mr. Denis SUPPLISSON, Deputy Chief Executive Officer

  • Resolution adopted by:
  • 11,138,885 votes for
  • 2,003,975 votes against
275 abstentionsApproval of the elements of compensation paid during the 2021 financial year to Mr. Grégoire de ROTALIER, Deputy Chief Executive Officer

  • Resolution adopted by:
  • 11,138,885 votes for
  • 2,003,975 votes against
275 abstentionsApproval of the compensation policy for the Chairman of the Board of Directors for 2022

  • Resolution adopted by:
  • 13,131,891 votes for
  • 11,210 votes against
34 abstentionsApproval of the compensation policy for Mr. Dominique PAUTRAT, Chief Executive Officer until April 22, 2022

  • Resolution adopted by:
  • 11,213,115 votes for
  • 1,929,745 votes against
275 abstentionsApproval of the compensation policy for Mr. Denis SUPPLISSON, Chief Executive Officer as of April 23, 2022

  • Resolution adopted by:
  • 11,056,710 votes for
  • 2,086,150 votes against
275 abstentionsApproval of the compensation policy for Mr. Denis SUPPLISSON, Deputy Chief Executive Officer until April 22, 2022

  • Resolution adopted by:
  • 11,056,710 votes for
  • 2,086,150 votes against
275 abstentionsApproval of the compensation policy for Grégoire de ROTALIER, Deputy Chief Executive Officer, for 2022

  • Resolution adopted by:
  • 11,056,710 votes for
  • 2,086,150 votes against
275 abstentionsApproval of the remuneration policy for Directors

  • Resolution adopted by:
  • 13,142,891 votes for
  • 210 votes against
34 abstentionsFixing of the overall annual remuneration of the Directors for 2022

  • Resolution adopted by:
  • 13,059,925 votes for
  • 83,210 votes against
0 abstentionsAuthorization to be given to the Board of Directors to operate on the Company’s shares

  • Resolution adopted by:
  • 11,477,951 votes for
  • 1,665,184 votes against
0 abstentionsPowers to complete formalities

  • Resolution adopted by:
  • 13,143,127 votes for
  • 0 votes against

8 abstentions

After deduction voting rights excluded

  • Calendarfinancial Publication of CA 1er semester 20

22 on August 3, 2022. About BandEquasens

: With moreof1. 2 00 collaborators “ Citizens of the health and from welfare “, the BandEquasens

eis today a structuring actor in the world of Health in Europe which addresses its software solutions to all health professionals (pharmacists, private doctors, hospitals, HAH structures, retirement homes, nursing homes of health) in the city as well as in the hospital. P present in France, Italy, Belgium, Luxembourg and Great Britain, the Band

Equasens is now developing the first health platform, a unique ecosystem in France and Europe, which puts the best of technology at the service of humans.

Listed on Euronext Paris™ – Compartment HAS Integrated on Euronext Tech Leaders and
with the European label Rising TechIndices: MSCI GLOBAL SMALL CAP – GAÏA Index 20 20– CAC® SMALL and CAC

® All-Tradable by inclusion
Eligible for the Deferred Settlement Service (SRD) and the PEA-SME scheme ISIN: FR0012882389 –Mnemonic code

EQ S Find all the news of the Group Equasens

on

www.equasens.com
CONTACTS
Investor Analyst Relations:

Administrative and Financial Director: Jean-Yves SAMSON
Such. 03 83 15 90 67 – [email protected]

Press relations :

  • FIN’EXTENSO – Isabelle APRILE

Such. 01 39 97 61 22 - i.aprile@finextenso.fr

EQUASENS_COMMUNIQUE_20220706_RESULTAT VOTES AG_ENPrimary Logo



Source link -88